Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20373254 | 1.00 | GLS (0.47) | GLSALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL18946127 | 0.81 | GLS (0.51) | GLS | |
| SCHEMBL22006507 | 0.81 | GLS (0.51) | GLS | |
| SCHEMBL17664538 | 0.79 | GLS (0.61) | GLSALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17654115 | 0.79 | GLS (0.61) | GLSALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL19434609 | 0.79 | GLS (0.61) | GLSALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17664476 | 0.77 | NPC1 (0.41) | GLSALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL19434646 | 0.77 | NPC1 (0.41) | GLSALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL17654168 | 0.76 | GLS (0.47) | GLSSMN1; SMN2HSD11B1 | |
| SCHEMBL17654177 | 0.75 | ALDH1A1 (0.59) | GLSALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-05-21 | — | — | US | disclosed |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-07-13 | — | — | US | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLRX3 | GLS 2/4885ALDH1A1 290/4885HPGD 682/4885 |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLRX3 | GLS 2/4885ALDH1A1 290/4885HPGD 682/4885 |
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | GLS 2/4885ALDH1A1 560/4885HPGD 815/4885 |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | GLS 2/4885ALDH1A1 575/4885HPGD 829/4885 |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | GLS 2/4885ALDH1A1 575/4885HPGD 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.